APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mental Illness Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mental Illness Drugs Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchMental Illness Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Mental Illness Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Mental Illness Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mental Illness Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Mental Illness Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Mental Illness Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mental Illness Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mental Illness Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mental Illness Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mental Illness Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mental Illness Drugs market include Johnson and Johnson, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mental Illness Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mental Illness Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mental Illness Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mental Illness Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Mental Illness Drugs Segment by Company

Johnson and Johnson

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Bristol-Myers Squibb

Mental Illness Drugs Segment by Type

Substance abuse treatments

Stimulants

Sleep disorder treatments

Cognitive disorders and dementia

Antidepressants

Antipsychotics

Antianxiety (anxiolyitcs)

Anti-seizure medications

Mental Illness Drugs Segment by Application

Drugstore

Hospital

Clinic

Mental Illness Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mental Illness Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mental Illness Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mental Illness Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Mental Illness Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mental Illness Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mental Illness Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mental Illness Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mental Illness Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mental Illness Drugs industry.

Chapter 3: Detailed analysis of Mental Illness Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mental Illness Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mental Illness Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mental Illness Drugs Industry Trends Table 2. Mental Illness Drugs Industry Drivers Table 3. Mental Illness Drugs Industry Opportunities and Challenges Table 4. Mental Illness Drugs Industry Restraints Table 5. Global Mental Illness Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mental Illness Drugs Revenue Share by Company (2021-2026) Table 7. Global Mental Illness Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Mental Illness Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Mental Illness Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Mental Illness Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mental Illness Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Mental Illness Drugs Company, Product Type & Application Table 13. Global Mental Illness Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mental Illness Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Substance abuse treatments Table 18. Significant Companies of Stimulants Table 19. Significant Companies of Sleep disorder treatments Table 20. Significant Companies of Cognitive disorders and dementia Table 21. Significant Companies of Antidepressants Table 22. Significant Companies of Antipsychotics Table 23. Significant Companies of Antianxiety (anxiolyitcs) Table 24. Significant Companies of Anti-seizure medications Table 25. Global Mental Illness Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Mental Illness Drugs Sales Volume by Type (2021-2026) & (k units) Table 27. Global Mental Illness Drugs Sales Volume by Type (2027-2032) & (k units) Table 28. Global Mental Illness Drugs Sales Volume Share by Type (2021-2026) Table 29. Global Mental Illness Drugs Sales Volume Share by Type (2027-2032) Table 30. Global Mental Illness Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Mental Illness Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Mental Illness Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Mental Illness Drugs Sales Value Share by Type (2021-2026) Table 34. Global Mental Illness Drugs Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Drugstore Table 36. Significant Companies of Hospital Table 37. Significant Companies of Clinic Table 38. Global Mental Illness Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Mental Illness Drugs Sales Volume by Application (2021-2026) & (k units) Table 40. Global Mental Illness Drugs Sales Volume by Application (2027-2032) & (k units) Table 41. Global Mental Illness Drugs Sales Volume Share by Application (2021-2026) Table 42. Global Mental Illness Drugs Sales Volume Share by Application (2027-2032) Table 43. Global Mental Illness Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Mental Illness Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Mental Illness Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Mental Illness Drugs Sales Value Share by Application (2021-2026) Table 47. Global Mental Illness Drugs Sales Value Share by Application (2027-2032) Table 48. Global Mental Illness Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 49. Global Mental Illness Drugs Sales by Region (2021-2026) & (k units) Table 50. Global Mental Illness Drugs Sales Market Share by Region (2021-2026) Table 51. Global Mental Illness Drugs Sales by Region (2027-2032) & (k units) Table 52. Global Mental Illness Drugs Sales Market Share by Region (2027-2032) Table 53. Global Mental Illness Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Mental Illness Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Mental Illness Drugs Sales Value Share by Region (2021-2026) Table 56. Global Mental Illness Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Mental Illness Drugs Sales Value Share by Region (2027-2032) Table 58. Global Mental Illness Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 59. Global Mental Illness Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 60. Global Mental Illness Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Global Mental Illness Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Mental Illness Drugs Sales by Country (2021-2026) & (k units) Table 63. Global Mental Illness Drugs Sales Market Share by Country (2021-2026) Table 64. Global Mental Illness Drugs Sales by Country (2027-2032) & (k units) Table 65. Global Mental Illness Drugs Sales Market Share by Country (2027-2032) Table 66. Global Mental Illness Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Mental Illness Drugs Sales Value Market Share by Country (2021-2026) Table 68. Global Mental Illness Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Mental Illness Drugs Sales Value Market Share by Country (2027-2032) Table 70. Johnson and Johnson Company Information Table 71. Johnson and Johnson Business Overview Table 72. Johnson and Johnson Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Johnson and Johnson Mental Illness Drugs Product Portfolio Table 74. Johnson and Johnson Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Eli Lilly Mental Illness Drugs Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Pfizer Mental Illness Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Mental Illness Drugs Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. AstraZeneca Mental Illness Drugs Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Bristol-Myers Squibb Company Information Table 96. Bristol-Myers Squibb Business Overview Table 97. Bristol-Myers Squibb Mental Illness Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Bristol-Myers Squibb Mental Illness Drugs Product Portfolio Table 99. Bristol-Myers Squibb Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Mental Illness Drugs Distributors List Table 103. Mental Illness Drugs Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Mental Illness Drugs Product Image Figure 2. Global Mental Illness Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mental Illness Drugs Sales (2021-2032) & (k units) Figure 5. Global Mental Illness Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Mental Illness Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Substance abuse treatments Image Figure 10. Stimulants Image Figure 11. Sleep disorder treatments Image Figure 12. Cognitive disorders and dementia Image Figure 13. Antidepressants Image Figure 14. Antipsychotics Image Figure 15. Antianxiety (anxiolyitcs) Image Figure 16. Anti-seizure medications Image Figure 17. Global Mental Illness Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Mental Illness Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Mental Illness Drugs Sales Volume Share by Type (2021-2032) Figure 20. Global Mental Illness Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Mental Illness Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Mental Illness Drugs Sales Value Share by Type (2021-2032) Figure 23. Drugstore Image Figure 24. Hospital Image Figure 25. Clinic Image Figure 26. Global Mental Illness Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Mental Illness Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Mental Illness Drugs Sales Volume Share by Application (2021-2032) Figure 29. Global Mental Illness Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Mental Illness Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Mental Illness Drugs Sales Value Share by Application (2021-2032) Figure 32. Global Mental Illness Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 33. Global Mental Illness Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Mental Illness Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Mental Illness Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. North America Mental Illness Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Mental Illness Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Mental Illness Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. South America Mental Illness Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Mental Illness Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Mental Illness Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Mental Illness Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Mental Illness Drugs Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Mental Illness Drugs Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Substance abuse treatments
  • Stimulants
  • Sleep disorder treatments
  • Cognitive disorders and dementia
  • Antidepressants
  • Antipsychotics
  • Antianxiety (anxiolyitcs)
  • Anti-seizure medications
Applications
  • Drugstore
  • Hospital
  • Clinic
Companies covered
  • Johnson and Johnson
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mental Illness Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Mental Illness Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Mental Illness Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mental Illness Drugs Market Dynamics
  1. 2.1 Mental Illness Drugs Industry Trends
  2. 2.2 Mental Illness Drugs Industry Drivers
  3. 2.3 Mental Illness Drugs Industry Opportunities and Challenges
  4. 2.4 Mental Illness Drugs Industry Restraints
3 Mental Illness Drugs Market by Company
  1. 3.1 Global Mental Illness Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Mental Illness Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Mental Illness Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Mental Illness Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Mental Illness Drugs Company Ranking (2024-2026)
  6. 3.6 Global Mental Illness Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Mental Illness Drugs Company Product Type and Application
  8. 3.8 Global Mental Illness Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mental Illness Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mental Illness Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mental Illness Drugs Market by Type
  1. 4.1 Mental Illness Drugs Type Introduction
  2. 4.1.1 Substance abuse treatments
  3. 4.1.2 Stimulants
  4. 4.1.3 Sleep disorder treatments
  5. 4.1.4 Cognitive disorders and dementia
  6. 4.1.5 Antidepressants
  7. 4.1.6 Antipsychotics
  8. 4.1.7 Antianxiety (anxiolyitcs)
  9. 4.1.8 Anti-seizure medications
  10. 4.2 Global Mental Illness Drugs Sales Volume by Type
  11. 4.2.1 Global Mental Illness Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Mental Illness Drugs Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Mental Illness Drugs Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Mental Illness Drugs Sales Value by Type
  15. 4.3.1 Global Mental Illness Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Mental Illness Drugs Sales Value by Type (2021-2032)
  17. 4.3.3 Global Mental Illness Drugs Sales Value Share by Type (2021-2032)
5 Mental Illness Drugs Market by Application
  1. 5.1 Mental Illness Drugs Application Introduction
  2. 5.1.1 Drugstore
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Mental Illness Drugs Sales Volume by Application
  6. 5.2.1 Global Mental Illness Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mental Illness Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Mental Illness Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Mental Illness Drugs Sales Value by Application
  10. 5.3.1 Global Mental Illness Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Mental Illness Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Mental Illness Drugs Sales Value Share by Application (2021-2032)
6 Mental Illness Drugs Regional Sales and Value Analysis
  1. 6.1 Global Mental Illness Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mental Illness Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Mental Illness Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Mental Illness Drugs Sales by Region (2027-2032)
  5. 6.3 Global Mental Illness Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mental Illness Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mental Illness Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mental Illness Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Mental Illness Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mental Illness Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Mental Illness Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mental Illness Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Mental Illness Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mental Illness Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mental Illness Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mental Illness Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Mental Illness Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mental Illness Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mental Illness Drugs Sales Value Share by Country, 2025 VS 2032
7 Mental Illness Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Mental Illness Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mental Illness Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mental Illness Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Mental Illness Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Mental Illness Drugs Sales by Country (2027-2032)
  6. 7.4 Global Mental Illness Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mental Illness Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mental Illness Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mental Illness Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mental Illness Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mental Illness Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson and Johnson
  2. 8.1.1 Johnson and Johnson Company Information
  3. 8.1.2 Johnson and Johnson Business Overview
  4. 8.1.3 Johnson and Johnson Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson and Johnson Mental Illness Drugs Product Portfolio
  6. 8.1.5 Johnson and Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Mental Illness Drugs Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Mental Illness Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Mental Illness Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Mental Illness Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Mental Illness Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Mental Illness Drugs Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mental Illness Drugs Value Chain Analysis
  2. 9.1.1 Mental Illness Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mental Illness Drugs Sales Mode & Process
  6. 9.2 Mental Illness Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mental Illness Drugs Distributors
  9. 9.2.3 Mental Illness Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst